
Rapacan 1mg tablet
Salt Composition: Sirolimus
Expiry Date: 01/2028
Inclusive of all taxes
10 Tablets in a Strip
About The Product
Breast cancer, Pancreatic cancer, Lung cancer, Kidney cancer
Description
Rapacan 1mg tablet is an immunosuppressant medication. It is used to prevent organ rejection in patients who have undergone a transplant.
The medication salt composition is Sirolimus, which belongs to the drug class mTOR inhibitors (mammalian target of rapamycin inhibitors). It works by suppressing the immune system to reduce the risk of the body attacking the transplanted organ.
A doctor's recommendation is necessary before using the tablet. Adults below the age of 18 should avoid using the medication to ensure their safety and the effectiveness of the medication.
Uses
- Help to prevent organ rejection in patients with kidney transplantation
Side Effects
Every medication has several side effects. Rapacan 1mg tablet may cause symptoms such as:
- Fatigue or weakness
- Nausea and vomiting
- Rash
- Infrequent, absent, or heavy periods
- Rapid heart rate
- High blood sugar
- Joint pain
- Acne
- Swelling of the body, including feet and hands
- Headache
- Fever, pain
- High blood pressure and cholesterol levels
- Constipation, diarrhea, stomach pain
How To Use
- The Rapacan 1mg tablet dosage and duration are correctly administered by the healthcare professional, as it can also cause various side effects.
- The medication can be taken orally at once daily at a fixed time every day with or without food.
- Dosage may vary depending on the patient's medical history and response to the treatment.
- Do not crush or chew the tablet, just swallow it whole.
How It Works
Rapacan 1mg tablet contains Sirolimus.
It works as an mTOR (mammalian target of rapamycin) inhibitor, which suppresses the immune response by inhibiting T cell activation and proliferation thereby helping to prevent organ transplant rejection and also inhibiting abnormal cell growth.
Safety Advice
FAQs
Rapacan 1mg tablet is used by patients who are undergoing kidney transplantation to prevent organ rejection.
References
- Sehgal, S. N. (2003, May). Sirolimus: its discovery, biological properties, and mechanism of action. In Transplantation proceedings (Vol. 35, No. 3, pp. S7-S14). Elsevier. https://pubmed.ncbi.nlm.nih.gov/12742462/
- Kahan, B. D. (2001). Sirolimus: a comprehensive review. Expert opinion on pharmacotherapy, 2(11), 1903-1917. https://pubmed.ncbi.nlm.nih.gov/11825325/
- Mahalati, K., & Kahan, B. D. (2001). Clinical pharmacokinetics of sirolimus. Clinical pharmacokinetics, 40(8), 573-585. https://pubmed.ncbi.nlm.nih.gov/11523724/
- McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., ... & Trapnell, B. C. (2011). Efficacy and safety of sirolimus in lymphangioleiomyomatosis. New England Journal of Medicine, 364(17), 1595-1606. https://pubmed.ncbi.nlm.nih.gov/21410393/
- Morath, C., Arns, W., Schwenger, V., Mehrabi, A., Fonouni, H., Schmidt, J., & Zeier, M. (2007). Sirolimus in renal transplantation. Nephrology Dialysis Transplantation, 22(suppl_8), viii61-viii65. https://pubmed.ncbi.nlm.nih.gov/17890266/
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
